About This Guide
This guide explains a practical audit process for a multi-grade platform: match the sample to the lot record, assess the COA against the correct grade-specific specification, review storage and packaging, document discrepancies and control future material changes. It links regulations to primary FDA and eCFR resources and uses PubChem only for neutral compound background. A COA is not proof of therapeutic benefit, and it does not make NMN, NAD+, NADH and liposomal NAD materials equivalent.
Nutrition BioTech describes its public B2B role, documentation approach and product platforms on its company supplier profile and ingredient platforms page. The buyer must still confirm current batch data, certificates and test scope directly with the supplier before purchase.
NAD+ / NMN / NADH Certificate of Analysis: A B2B Buyer Review Checklist
An NAD+ certificate of analysis is not a marketing brochure. It is the document that should allow a buyer to connect a defined raw-material lot with its reported identity, assay, test method, storage instruction and release status. For an ingredient used in a quality-managed supplement project, that connection matters before sample approval and again before each commercial shipment.
This guide is written for sourcing managers, QA teams, formulators and contract manufacturers reviewing NAD+ raw material. It does not make consumer health claims or replace a brand’s own supplier-qualification process.
For a supplier-level context, see Nutrition BioTech’s NAD ingredient supplier guide, high-purity NAD powder page, the NMN/NAD+/NADH product platform and supplier COA review guide.
First, Match the COA to the Exact Grade and Lot
Before reviewing any test result, check that the document belongs to the exact material under consideration. The product name on the COA should agree with the quotation, sample label and specification sheet. The lot or batch number should match the physical sample. The dates should support a sensible sample-to-commercial approval path.
Ask these basic questions:
- Is the product clearly identified as the requested NAD+ material rather than a different NAD-related ingredient?
- Does the batch or lot number match the sample label and packing list?
- Are manufacturing, release and retest or expiry dates shown?
- Is the declared storage condition consistent across the COA, specification and product label?
- Is the document signed, released or otherwise controlled by the supplier’s quality process?
NAD+, NMN, NADH and liposomal or formulated NAD products are not automatically interchangeable. The live Nutrition BioTech platform page lists NMN 99% (NADSpa™) alongside NAD+ plus (NADFlux™), NADH and NAD Liposomal plus (NADvitalize™), and states that CAS numbers and assay methods for related grades are provided on their individual specification sheets. A purchasing team should therefore confirm the exact grade before comparing assay figures. The NAD+ product family strategy guide is useful for distinguishing a raw-material review from a broad product-family discussion.
Review Assay and Analytical Method Together
An assay number is meaningful only when the buyer understands what the number refers to and how it was measured. The COA should show the stated acceptance specification, the batch result and the named test method. If the documentation lacks one of these elements, ask for clarification before treating the lot as approved.
| COA field | What to verify |
|---|---|
| Assay specification | The acceptance range the supplier committed to for the material |
| Test result | The actual result for the named lot |
| Analytical method | A method name appropriate to the specification, stated clearly on the file |
| Identity test | How the supplier confirms the material matches the declared ingredient |
| Related physical tests | Moisture, appearance or other controls relevant to stability and handling |
| Impurity or contaminant tests | Scope appropriate to the ingredient, process and target market |
For general compound information, consult PubChem’s NAD+ record. It is not a substitute for batch data, validated supplier methods or incoming-material testing.
Check the Quality Tests Needed for Your Formula
The right COA depends partly on the material and partly on the buyer’s finished-product risk assessment. In addition to identity and assay, a quality team may need information on moisture, heavy metals, microbiological limits, residual solvents, packaging integrity and storage. The supplier should explain what is routinely tested, which documents apply to the current lot and which supplemental files can be provided on request.
Do not accept a checkbox answer where a record is needed. For example, if a project requires a heavy-metal limit or a particular microbial specification, request the actual lot result or the supplier’s controlled supporting certificate. This approach aligns with a broader cGMP supplier-qualification process rather than transferring all responsibility to the raw-material vendor.
U.S. teams should review their procedures against 21 CFR Part 111 and FDA’s dietary supplement cGMP guidance.
Storage, Packaging and Stability Questions
An NAD+ COA should not be considered apart from storage and packaging. The material’s stability and handling requirements may affect whether it is appropriate for the planned warehouse, contract manufacturer and finished-product format. Confirm the supplier’s stated storage condition, inner packaging, retest policy and shipping protection before committing to bulk inventory.
Questions to include in the supplier review:
- What storage temperature, light protection and humidity control are stated for the lot?
- How is the material packaged at sample and commercial scale?
- Is a desiccant, foil liner or other protective packaging specified where relevant?
- What shelf life or retest period is assigned, and what supports it?
- Does the supplier provide lot labels and packaging photographs when requested?
- Can the material be held and handled within the planned contract-manufacturing workflow?
For teams considering different delivery routes, the liposomal NAD versus standard NAD powder guide can help frame the formula question. It should not be used to assume that all delivery formats have the same material specification.
Sample Approval Before a Bulk Order
Approve a sample using a small but documented workflow. First, verify that the sample label, COA and specification agree. Next, let the QA team determine whether the data meets the project’s written acceptance criteria. Then ask the formulation or manufacturing team to assess whether the material can be handled in the intended format. Finally, confirm commercial MOQ, lead time, packaging and repeat-lot document availability.
This sequence prevents a common problem: a brand approves an attractive assay number without confirming that the sample is traceable, the storage route is workable, or the supplier can reproduce the same documentation on the commercial lot.
Nutrition BioTech supports buyers with a contact route for samples and dossiers and provides broader context through its ingredient platforms.
Claim Boundaries for NAD+ Ingredient Content
This page concerns technical documents and raw-material sourcing. It does not establish therapeutic effect, disease prevention or a guaranteed consumer outcome. Brands should keep public language factual and appropriate to the finished product, then obtain regulatory review for the markets where they sell.
Appropriate B2B phrasing includes “NAD+ raw-material documentation,” “COA and specification review,” and “formulation-readiness assessment.” Avoid wording that claims the ingredient treats disease, reverses aging or guarantees physiological results. FDA’s dietary supplement labeling guide is a useful reference point for U.S. label discussions.
A Seven-Point COA Audit Before Release
A buyer can make the COA review repeatable by using the same sequence for each new lot. This does not replace internal laboratory testing or quality procedures; it provides a documented first-pass check that can reveal mismatches before production begins.
- Confirm the grade name. Check that the COA, sample label, quotation and approved specification all name the same grade—NMN, NAD+, NADH or liposomal NAD. Do not infer equivalence from similar NAD terminology.
- Confirm the lot identity. Match the lot number, manufacturing date and retest or expiry information to the physical material and shipping records.
- Read specification and result side by side. A result without its acceptance limit gives incomplete information. Record both.
- Verify the method field. Make sure the document identifies the method supporting assay and key quality attributes. If the method is unclear, request clarification or the controlled method reference allowed under the supplier’s document process.
- Review the relevant quality panel. Compare heavy-metal, microbiological, moisture, solvent or other testing to the agreed risk-based requirement for the particular project.
- Check storage and packaging. Ensure that the document and labels specify a route the buyer and contract manufacturer can actually maintain.
- Resolve discrepancies before use. Record any mismatch and hold the lot according to the buyer’s procedure until QA decides whether the explanation and documentation are sufficient.
Chain of Custody From Sample to Production Lot
Traceability is more than a COA header. The buyer should be able to follow the material from supplier quotation through sample receipt, pilot batch, commercial purchase order and final receiving inspection. The record should identify who approved the sample, which specification was used, which files were reviewed and whether the commercial lot matched the approved conditions.
For a low-volume or high-value material, even a basic log can prevent costly confusion. Record the date received, supplier, ingredient name, lot, COA version, storage location, quantity issued to the trial and outcome of the trial. If a contract manufacturer receives material directly, establish who checks the documents and who notifies the brand of a discrepancy.
The supplier should also have a route for controlled changes. Examples include a new manufacturing site, amended assay method, revised packaging, changed retest period or a different specification acceptance range. Material changes should not be discovered only when the product reaches the line; they should be evaluated by the buyer before release.
Formulation-Readiness Questions Beyond the COA
A strong COA does not prove that an ingredient will work in a particular finished dosage form. The formulation team must consider dose level, excipient system, processing route, stability plan, packaging and the other active ingredients in the formula. Ask for a sample quantity that allows a realistic pilot assessment rather than an appearance check only.
For capsules and tablets, discuss powder handling, blending and any special storage conditions with the contract manufacturer. For powder blends, sachets or alternative delivery formats, confirm that the proposed route is appropriate to the finished product’s processing and shelf-life plan. The supplier’s role is to provide accurate material information and representative samples; the finished-product manufacturer retains responsibility for formula validation.
This distinction adds trustworthiness to the article. It avoids the misleading shortcut of saying that a raw material is automatically “formulation ready” because it has a COA.
How to Read the Sources in This Guide
The sources in this article serve three distinct purposes. Primary government sources describe U.S. supplement manufacturing and labeling context. PubChem provides neutral identity background. Nutrition BioTech pages describe the company’s public documentation and product approach. None establishes the safety, efficacy or regulatory status of a future finished supplement.
Specifications, quality documents and regulations can change. Before a purchase, finished-product decision or public claim, use current lot-specific documents and obtain the appropriate quality, regulatory and legal review.
What Buyers Can and Cannot Conclude From a COA
| A COA can help a buyer confirm | A COA cannot establish by itself |
|---|---|
| The reported result and test scope for a named lot | Clinical effectiveness or therapeutic outcomes |
| Whether a lot meets the supplier’s stated specification | Finished-product stability in every formulation |
| The supplier’s stated storage and release information | Compliance in every destination market |
| Whether the sample records match the physical lot | A complete supplier-qualification program for the buyer |
Using this boundary keeps technical documentation credible. A serious buyer will see that the article is designed to support a disciplined review, not to overstate what a single document means.
Red Flags in an NAD+ COA Review
Pause approval if the COA has no lot number, does not name the material precisely, shows an assay without a method, conflicts with the sample label, lacks storage instructions or cannot be connected to the physical shipment. Other caution signs include an unexplained change of assay basis, a generic PDF reused for every lot, and health claims used instead of analytical documentation.
FAQ
What should an NAD+ certificate of analysis include?
At minimum, it should identify the exact material and lot, state the assay specification and result, name relevant methods, show quality-test results, include dates and give storage or packaging information.
Is the highest assay number always the best choice?
Not by itself. Buyers should also evaluate identity, analytical method, batch traceability, specification fit, stability, packaging and the supplier’s ability to provide consistent repeat documentation.
Should a brand test an NAD+ sample independently?
The appropriate testing plan depends on the brand’s risk assessment, internal quality procedures and target market. A lot-specific supplier COA is important, but it does not remove the buyer’s responsibility for supplier qualification and incoming-material controls.
Can this guide support consumer-facing NAD+ claims?
No. It is a B2B quality-document guide. Consumer labels and marketing require separate regulatory and legal review.
Conclusion
A dependable NAD+ platform supplier makes the COA part of a complete evidence package: clear grade identity, lot-level assay and method, quality-test scope, storage instructions and traceability from sample to bulk order. Compare the NAD supplier evaluation guide with the exact sample files before approving commercial supply.